Back to News
Market Impact: 0.25
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Source: globenewswire.com
Healthcare & Biotech
The trial met its primary and secondary endpoints, showing statistically significant placebo-adjusted improvements at Week 3: 3.1 points on the YMRS total score (p=0.045) and 0.4 points on the CGI-BP Severity of Mania score (p=0.024). The excerpt provides no details on the treatment, trial size, or further outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Why is Intuitive Surgical stock sliding today?
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Alpha Teknova stock tumbles on public offering announcement
- Disc Medicine prices $450 million stock offering at $75/share
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace